Testosterone Therapy and Prostate Cancer
Main article details obtained from the US National Library of Medicine
Testosterone Therapy and Prostate Cancer
Prostate Cancer and Testosterone Therapy and Prostate cancer is a considerably well-known paradox, right? Did you know that there is actually a lack of evidence for testosterone therapy causing prostate cancer? We have actually presented doctors and interested people at seminars an alternative view to the misdirection that Harvard’s Chief of Urology made in the 1930’s. Mistakes so egregious that they are still quoted as fact unto this very day. The most outlandish mistake acknowledged a few years ago by Harvard Medical Review Board was the error in the 1930’s research concluding that testosterone caused prostate cancer.
- The peer-reviewed article in a leading Urological Journal below explains in great detail that the modern research into this issue shows, once again, no relationship at all between an increase in prostate cancers and even PSI’s and testosterone replacement therapy.
This Peer Reviewed scientific Article was written by Dr. Michael K Brawer M.D., one of the foremost Research Urologists in the USA. He has written over 200 articles, 25 books and 74 government funded grants to study testosterone’s effect on the prostate.
What does this mean for our presentation of this issue at AAI Rejuvenation Clinic? We think it’s definitely a promising twist that deserves to be presented to interested clients and patients, explaining that:
- More recent advances in urological research show no connection between testosterone and an increased risk of prostate cancer.
- There is only one peer-reviewed study in patients with advanced prostate cancer, that testosterone was shown to have any deleterious effect on a prostate which already had advanced cancer.
- This is the route taken by Dr. Janine Cabanellas M.D. a Harvard-trained Dr. who now owns the Wellington Institute of wellness and Anti-Aging.
We at AAI Clinics want to express that our interest is to stay on top of the latest and most up-to-date medical advances and research. We also aim to continually educate our clients and patients with these informational pieces as they surface, even if only in the form of an intellectual discussion, such as this one. A meeting of the minds, if you will.
Retrospectively, despite the more recent studies pointing to the fact that the connection between testosterone therapy and prostate cancer may be a high-profile medical misconception, until the general, medical consensus has agreed and changed in their direction of treatment, the physicians here at AAI center their patient’s therapies with all the precautionary necessities and medications.
- In fact, we are one of the only clinics that have a designated section for accompanying nutraceuticals significant to the patient’s therapy and focused on minimizing any possible side effects.
- Our nutraceuticals come exclusively from Douglas Labs.
- Do your own research. Everyone says they are the best. Douglas labs have the documentation and FDA seals of approval to back the claims.
One of the best nutraceuticals to take while on testosterone therapy (or even if you are not on testosterone therapy) to focus on the health of the prostate is TestoQuench for men. Definitely, check it out. Call us up for $10 off per medication during the next 10 days:
The effect of hormonal regulation of prostatic tissue growth and function, particularly reflected by serum PSA level, is, of course, a well-studied area. Particular attention has been paid to the effect of androgen withdrawal as a treatment of prostatic carcinoma.
- Several investigations have attempted to correlate serum PSA levels with testosterone levels.
- Two studies, those of Behre and associates and Svetec demonstrated statistically significantly lower levels of PSA in hypogonadal men than normal men.
- Four other investigations revealed a trend toward lower levels of PSA in hypogonadal men, although this trend did not achieve statistical significance in any of the studies.
Several investigators have measured PSA levels before and after testosterone replacement.
- In six reports PSA was found to increase significantly after testosterone replacement.
- In others, although there was a tendency for PSA to increase, this trend did not reach statistical significance.
- In only one study investigating this phenomenon, that of Snyder et al, did the PSA level remain unchanged?
- Three investigators simply looked at the chance of PSA increasing to above the threshold of normal (4.0 ng/mL). In none of these studies did this increase occur.
- A number of animal models have demonstrated that exogenous androgens stimulate established prostate cancer in a dose-dependent fashion. Testosterone given to patients with advanced metastatic prostate cancer results in severe pain at bony metastatic sites.
- There have been three investigations in which supplemental testosterone was given to eugonadal men. Indications were obesity with low normal testosterone, in healthy volunteers, and in men in a long-term contraception trial. In none of these investigations on eugonadal men was an increase in PSA observed.
- Again, due to the lack of agreement in the study results, no relationship between serum testosterone and PSA was established.
Cancer Risk and Patient Monitoring
Despite the conclusion that it is highly doubtful that the administration of testosterone therapy produces any promotional effect in the absence of an already existing cancer, the patient needs to be monitored. A standard urologic evaluation to rule out malignancy should be undertaken prior to initiating androgen supplementation. Recommendations include a carefully performed digital rectal examination (DRE) along with serum PSA measurements. If either the rectal examination is abnormal or the PSA level exceeds 4.0 ng/mL, ultrasound-guided prostate biopsy becomes mandatory. If the initial PSA levels are within normal limits and the DRE is negative, one should feel comfortable initiating androgen supplementation in properly identified patients. It is imperative that the patient is carefully monitored for any changes in these prostate risk findings and we would recommend reassessment at 3 months. At that time, if the PSA level exceeds 4.0 ng/mL, or there is a change in DRE, the prostate biopsy is warranted. We recommend an additional prostate assessment in 3 more months (6 months after initiating therapy) and at least annually thereafter.
The effectiveness of testosterone therapy in ameliorating the signs and symptoms of hypogonadism in the aging male will lead to increased implementation of this therapy. There have been multiple attempts to correlate the administration of testosterone to prostate carcinogenesis, but the studies have failed to produce consistent results. Similarly, the studies which attempt to correlate increased testosterone with increased PSA levels have been unconvincing. Nor have the studies been able to link DHT, the more active metabolite of testosterone, to the development of carcinoma. The prevailing opinion is that restoring your low testosterone levels to physiologic levels offers no increased risk of carcinoma. However, there is little doubt that the studies show a deleterious effect on existing clinical carcinoma of the prostate. With the elimination of the presence of an existing carcinoma of the prostate, through physical examination and laboratory studies, before initiation of testosterone therapy, and the continuous monitoring of the patient throughout therapy, testosterone injections therapy will prove safe with regard to prostate health.